Evidence map›Paper›PMID 40888475›Full record

ArticleeLife2025

Development of D-box peptides to inhibit the anaphase-promoting complex/cyclosome.

Rohan Eapen, Cynthia Okoye, Christopher Stubbs, Marianne Schimpl, Thomas Tischer, Eileen J Fisher, Maria Zacharopoulou, Fernando Ferrer, David Barford, David R Spring and 3 more

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rohan EapenDepartment of Pharmacology, University of Cambridge, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0001-7269-3633
Cynthia OkoyeDepartment of Pharmacology, University of Cambridge, Cambridge, United Kingdom.
Christopher StubbsAstraZeneca, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0002-2373-5478
Marianne SchimplAstraZeneca, Cambridge, United Kingdom.
Thomas TischerMRC Laboratory of Molecular Biology, Cambridge, United Kingdom.
Eileen J FisherAstraZeneca, Cambridge, United Kingdom.
Maria ZacharopoulouDepartment of Pharmacology, University of Cambridge, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0002-3660-2797
Fernando Ferrerp53 Laboratory, Singapore, Singapore.
David BarfordMRC Laboratory of Molecular Biology, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0001-8810-950X
David R SpringYusuf Hamid Department of Chemistry, University of Cambridge, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0001-7355-2824
Catherine LindonDepartment of Pharmacology, University of Cambridge, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0003-3554-2574
Christopher PhillipsAstraZeneca, Cambridge, United Kingdom.
Laura S ItzhakiDepartment of Pharmacology, University of Cambridge, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0001-6504-2576

Funding

Biotechnology and Biological Sciences Research Council BB/R004137/1Cancer Research UK C17838/A27225Human Frontier Science Program 10.52044/hfsp.rgp00272020.pc.gr.165420
6 · The paper itself

Abstract

E3 ubiquitin ligases engage their substrates via 'degrons' - short linear motifs typically located within intrinsically disordered regions of substrates. As these enzymes are large, multi-subunit complexes that generally lack natural small-molecule ligands and are difficult to inhibit via conventional means, alternative strategies are needed to target them in diseases, and peptide-based inhibitors derived from degrons represent a promising approach. Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase-promoting complex/cyclosome (APC/C) that is essential in mitosis and consequently of interest as an anti-cancer target. APC/C engages substrates via degrons that include the 'destruction box' (D-box) motif. We used a rational design approach to construct binders containing unnatural amino acids aimed at better filling a hydrophobic pocket that contributes to the D-box binding site on the surface of Cdc20. We confirmed binding by thermal-shift assays and surface plasmon resonance and determined the structures of a number of the Cdc20-peptide complexes. Using a cellular thermal shift assay, we confirmed that the D-box peptides also bind to and stabilise Cdc20 in the cell. We found that the D-box peptides inhibit ubiquitination activity of APC/C

Indexed as

Anaphase-Promoting Complex-CyclosomeCdc20 ProteinsPeptidesHumansProtein BindingAnaphase-Promoting Complex-CyclosomeCDC20 protein, humanCdc20 ProteinsPeptidesanaphase-promoting complex/cyclosomeAPC/Cbiochemistrychemical biologydegronE. colihumanpeptide inhibitorprotein–protein interactionubiquitin

Identifiers

PMID40888475
PMCPMC12401543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.